Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | WHR1 | P49842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26112460 | 1.00 | EGFR (0.35) | EGFRERBB2HCRTR1HCRTR2IRAK4 | |
| SCHEMBL26112695 | 1.00 | EGFR (0.35) | EGFRERBB2HCRTR1HCRTR2IRAK4 | |
| SCHEMBL26112581 | 0.93 | EGFR (0.36) | EGFRERBB2HCRTR1HCRTR2PDGFRB | |
| SCHEMBL26113701 | 0.90 | IRAK4 (0.36) | EGFRERBB2HCRTR1HCRTR2IRAK4 | |
| SCHEMBL30590846 | 0.89 | WNT1 (0.35) | EGFRERBB2HCRTR1HCRTR2IRAK4 | |
| SCHEMBL26111725 | 0.89 | WNT1 (0.35) | EGFRERBB2HCRTR1HCRTR2IRAK4 | |
| SCHEMBL30590886 | 0.88 | EGFR (0.35) | EGFRERBB2HCRTR1HCRTR2PDGFRB | |
| SCHEMBL26112646 | 0.87 | CSNK1D (0.40) | EGFRCSNK1DCSNK1E | |
| SCHEMBL26112337 | 0.86 | HCRTR1 (0.36) | EGFRERBB2HCRTR1HCRTR2IRAK4 | |
| SCHEMBL26113154 | 0.86 | HCRTR1 (0.36) | EGFRERBB2HCRTR1HCRTR2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325471-A | EGFR inhibitors | 缆图药品公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885HCRTR1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.